SD-101 With Immune Checkpoint Inhibition Generates Positive Results in Uveal Melanoma Liver Metastasis
Source: OncLive, December 2023
Treatment with SD-101 distributed via pressure-enabled drug delivery with immune checkpoint inhibition was tolerated and resulted in the depletion of regulatory T cells (Tregs), monocytic myeloid-derived suppressor cells (M-MDSCs), and M2 macrophages in liver metastases in patients with uveal melanoma, according to data from the phase 1 PERIO-01 trial (NCT04935229) presented at the 2023 SITC Annual Meeting.
The results showed that treatment with 2 mg of SD-101 plus nivolumab (Opdivo) led to a median progression-free survival (PFS) of 11.7 months and 1-year overall survival (OS) rate of 86%.
“When we look at this all together, we see the most favorable immune reprogramming happening at the 2 mg plus nivolumab dose level,” Sapna Patel, BA, MD, said in a presentation of the data. “This is demonstrated by a decrease in regulatory T cells and M-MDSCs in the liver tumors, and an increase in systemic activation via cytokine signaling and circulating T cells and NK cells in the periphery,” Patel said.